ADVERTISEMENT

Pharma Q3 Results Preview - Better Performance Led By New Launches, Profitability: Axis Securities

We recommend 'Buy' on Lupin, Aurobindo, Cipla, Abbott India, and KIMS. These companies may surpass the industry growth driven by a superior product portfolio and strong product pipeline.

<div class="paragraphs"><p>Medicines arranged for photograph. (Source: pixabay pexels )</p></div>
Medicines arranged for photograph. (Source: pixabay pexels )
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More